JP2023519837A5 - - Google Patents

Info

Publication number
JP2023519837A5
JP2023519837A5 JP2022557696A JP2022557696A JP2023519837A5 JP 2023519837 A5 JP2023519837 A5 JP 2023519837A5 JP 2022557696 A JP2022557696 A JP 2022557696A JP 2022557696 A JP2022557696 A JP 2022557696A JP 2023519837 A5 JP2023519837 A5 JP 2023519837A5
Authority
JP
Japan
Prior art keywords
expression vector
single expression
elements
vlp
vector encodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000190 external-priority patent/WO2021198769A1/en
Publication of JP2023519837A publication Critical patent/JP2023519837A/ja
Publication of JP2023519837A5 publication Critical patent/JP2023519837A5/ja
Pending legal-status Critical Current

Links

JP2022557696A 2020-03-30 2021-03-30 コロナウイルスを処置するためのワクチン組成物 Pending JP2023519837A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002237P 2020-03-30 2020-03-30
US63/002,237 2020-03-30
US202063070150P 2020-08-25 2020-08-25
US63/070,150 2020-08-25
PCT/IB2021/000190 WO2021198769A1 (en) 2020-03-30 2021-03-30 Vaccine compositions for the treatment of coronavirus

Publications (2)

Publication Number Publication Date
JP2023519837A JP2023519837A (ja) 2023-05-15
JP2023519837A5 true JP2023519837A5 (cg-RX-API-DMAC7.html) 2024-04-01

Family

ID=77927072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557696A Pending JP2023519837A (ja) 2020-03-30 2021-03-30 コロナウイルスを処置するためのワクチン組成物

Country Status (10)

Country Link
US (1) US11253587B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126038A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023519837A (cg-RX-API-DMAC7.html)
KR (1) KR20230008707A (cg-RX-API-DMAC7.html)
AU (1) AU2021247583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019672A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142132C (cg-RX-API-DMAC7.html)
IL (1) IL296578A (cg-RX-API-DMAC7.html)
MX (1) MX2022012192A (cg-RX-API-DMAC7.html)
WO (1) WO2021198769A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
US20230174591A1 (en) * 2020-05-19 2023-06-08 National Research Council Of Canada Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections
KR102744743B1 (ko) * 2021-10-25 2024-12-19 경희대학교 산학협력단 SARS-CoV-2의 스파이크 단백질 전부 또는 일부를 포함하는 바이러스 유사입자 및 이를 이용한 백신
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
CA2568838A1 (en) 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
AU2009316680B2 (en) 2008-11-18 2016-03-24 Takeda Vaccines, Inc. RSV F VLPs and methods of manufacture and use thereof
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
WO2011115583A1 (en) * 2010-03-19 2011-09-22 National University Of Singapore A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens
WO2014128568A2 (en) * 2013-02-25 2014-08-28 Variation Biotechnologies, Inc. Compositions and methods for treatment of hepatitis c
MX2019000725A (es) * 2016-07-18 2019-07-04 Variation Biotechnologies Inc Composiciones de vacuna para tratamiento de virus zika.

Similar Documents

Publication Publication Date Title
EP2359851A3 (en) MVA expressing modified hiv envelope, gag, and pol genes
Freed HIV-1 replication
Eschli et al. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins
Fäcke et al. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum
LaBranche et al. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells
MX2023000156A (es) Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
Moulard et al. Processing and routage of HIV glycoproteins by furin to the cell surface
DK1372710T3 (da) MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener
DK1402015T3 (da) Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
AR029759A1 (es) Variante de glucoamilasa original, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de fermentacion y metodo para mejorar la estabilidad termica.
Ritter Jr et al. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain
JP2012509340A5 (cg-RX-API-DMAC7.html)
JP2004533208A5 (cg-RX-API-DMAC7.html)
BRPI0509497A (pt) seqüência de polipeptìdeos na modulação do efeito imunosupressor de proteìnas virais
Jayaraman et al. Oligomeric viral proteins: small in size, large in presence
Cifuentes-Munoz et al. Aromatic and polar residues spanning the candidate fusion peptide of the Andes virus Gc protein are essential for membrane fusion and infection
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
WO2006026667A3 (en) Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
Jackson et al. Sequence and functional variation in the HIV-1 Rev regulatory axis
Bour et al. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release
Vincent et al. Intracellular interaction of simian immunodeficiency virus Gag and Env proteins
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
Manrique et al. Functional relationship between the matrix proteins of feline and simian immunodeficiency viruses
JP2004520009A5 (cg-RX-API-DMAC7.html)
WO2004108886A3 (en) Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein